PLEASANTON, Calif., Aug. 13, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that industry leaders from AbbVie, Astellas, Eikon Therapeutics, Merck & Co., Moderna, and Roche will keynote at the upcoming 2024 Veeva R&D and Quality Summit in Boston on Sept. 9-10. Professionals across life sciences will come together to discuss how connected systems across clinical, regulatory, safety, and quality can move the industry forward for the benefit of patients.
Veeva R&D and Quality Summit is one of the largest life sciences events, drawing more than 2,000 executives to network and learn across more than 100 sessions. Veeva CEO Peter Gassner headlines the opening keynote, sharing innovations and examples of how connected data and systems can significantly streamline drug development and accelerate product time to market. Additional featured keynotes and sessions include:
"Veeva is committed to customer success, delivering integrated software, data, and services that can advance innovation for patients in need," said Jim Reilly, vice president of Veeva Development Cloud strategy. "Veeva R&D and Quality Summit brings the industry together to share learnings, fresh ideas, and new strategies to improve collaboration and accelerate the delivery of novel products."
The event is open exclusively to life sciences professionals. Register and stay up to date on the agenda at veeva.com/Summit.
Additional Information
Register for Veeva R&D and Quality Summit: veeva.com/Summit/register
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Contact:
Deivis Mercado
Veeva Systems
925-226-8821
This email address is being protected from spambots. You need JavaScript enabled to view it.

| Last Trade: | US$217.05 |
| Daily Change: | 1.58 0.73 |
| Daily Volume: | 1,582,051 |
| Market Cap: | US$35.680B |
December 04, 2025 December 03, 2025 November 24, 2025 November 20, 2025 November 04, 2025 | |

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load